High-sensitivity C-reactive protein and interleukin-6 as risk predictors in patients with stable angina pectoris

Shekhar Kunal, Pradeep Kumar Meena, Pooja Pathak, Himanshu Mahla, Kashish Gupta, Vijay Pathak


Background: Cardiovascular diseases are a leading cause of morbidity and mortality especially in developing countries such as India. Biomarkers such as high-sensitivity C-reactive protein (Hs-CRP) and interleukin-6 (IL-6) can help in risk stratification and better management of patients with stable angina.

Methods: This was a prospective observational study wherein symptomatic patients with stable angina were enrolled. Coronary angiogram was done in those consenting to the procedure. Severity of coronary stenosis was graded as per the modified Gensini score (mGS). Hs-CRP and IL-6 levels were determined pre-procedure and 24 hours post percutaneous coronary intervention (PCI). Based on angiographic profile, patients were subdivided into four groups: group 1: normal coronaries, group 2: single vessel disease, group 3: double vessel disease and group 4: triple vessel disease. Primary outcome was occurrence of major adverse cardiovascular events over one-year period.

Results: A total of 158 patients completed the study with a mean age of 62.8±9.6 years. A significant difference was observed between the four groups in terms of age, Hs-CRP and IL-6 levels. Of the 124 patients undergoing PCI, significant difference was observed in terms of pre and post procedure Hs-CRP (P<0.0001) and IL-6 levels (P<0.0001). Strong positive correlation was seen between Hs-CRP and IL-6 levels with modified Gensini scoring (mGS). Patients with MACE (15/158; 9.4%) had significantly higher levels of Hs-CRP and IL-6. Multivariate logistic regression analysis revealed that Hs-CRP, IL-6, ΔHs-CRP and ΔIL-6 were independent predictors of major adverse cardiovascular events (MACE).

Conclusions: Hs-CRP and IL-6 levels were independent predictors of outcomes and can be used for risk stratification in these patients.



Angina pectoris, Biomarkers, Coronary angiogram, Coronary artery disease, Interleukin-6, High sensitivity C-reactive protein

Full Text:



Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1-25.

Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97:596-601.

Lusis AJ. Atherosclerosis. Nature. 2000;407:233-41.

Madjid M, Willerson JT. Inflammatory markers in coronary heart disease. Br Med Bull. 2011;100:23-38

Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.

Li H, Sun K, Zhao R, Hu J, Hao Z, Wang F, et al. Inflammatory biomarkers of coronary heart disease. Front Biosci (Schol Ed). 2018;10:185-96.

Roberts WL. Workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: laboratory tests available to assess inflammation-performance and standardization: a background paper. Circulation. 2004;110(25):572-6.

Thompson DK, Huffman KM, Kraus WE, Kraus VB. Critical appraisal of four IL-6 immunoassays. PLoS One. 2012;7:30659.

Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606

Youngstrom EA. A primer on receiver operating characteristic analysis and diagnostic efficiency statistics for pediatric psychology: we are ready to ROC. J Pediatr Psychol. 2014;39:204-21.

Peer A, Falkensammer G, Alber H, Kroiss A, Griesmacher A, Ulmer H, et al. Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease. Heart. 2009;95:297-303.

Hosseinsabet A, Mohebbi A, Almasi A. Association between C-reactive protein and coronary calcium score in coronary artery disease. Cardiovasc J Afr. 2009;20:107-11.

Lin T, Liu JC, Chang LY, Shen CW. Association of C-reactive protein and homocysteine with subclinical coronary plaque subtype and stenosis using low-dose MDCT coronary angiography. Atherosclerosis. 2010;212:501-6.

He P, Xie XH, Ding YP, Chen XL. Correlation between high sensitive C-reactive protein, lipoprotein, blood uric acid and severity of coronary artery disease. Zhonghua Yi Xue Za Zhi. 2010;90:1989-91.

Masood A, Jafar SS, Akram Z. Serum high sensitivity C-reactive protein levels and the severity of coronary atherosclerosis assessed by angiographic gensini score. J Pak Med Assoc. 2011;61:325-7.

Bamberg F, Truong QA, Koenig W, Schlett CL, Nasir K, Butler J, et al. Differential associations between blood biomarkers of inflammation, oxidation, and lipid metabolism with varying forms of coronary atherosclerotic plaque as quantified by coronary CT angiography. Int J Cardiovasc Imaging. 2012;28:183-92.

Barbero U, D'Ascenzo F, Nijhoff F, Moretti C, Biondi-Zoccai G, Mennuni M, et al. Assessing risk in patients with stable coronary disease: when should we intensify care and follow-up? results from a meta-analysis of observational studies of the COURAGE and FAME era. Scientifica (Cairo). 2016;3769152.

Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, et al; Atherogene investigators. impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: atheroGene study. Eur Heart J. 2006;27:2962-8.

Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al; PEACE investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007;115:1528-36.

Mokhtar ER, Saleh BI, Aboualia AM, Nageb HM. Relationship between monocyte subsets, IL-6 and hs-CRP with the severity of coronary artery disease in stable angina pectoris patients. Am J Biochem. 2017;7:114-26.

Sarrafzadegan N, Sadeghi M, Ghaffarpasand F, Alisaeidi A, Sanei H, Zakeri H, et al. Interleukin-6 and E-selectin in acute coronary syndromes and stable angina pectoris. A comparative study. Herz. 2012;37:926-30.

Tang JN, Shen DL, Liu CL, Wang XF, Zhang L, Xuan XX, et al. Plasma levels of C1q/TNF-related protein 1 and interleukin 6 in patients with acute coronary syndrome or stable angina pectoris. Am J Med Sci. 2015;349:130-6.

Caselli C, De Graaf MA, Lorenzoni V, Rovai D, Marinelli M, Del Ry S, et al. HDL cholesterol, leptin and interleukin-6 predict high risk coronary anatomy assessed by CT angiography in patients with stable chest pain. Atherosclerosis. 2015;241:55-61.

Liu CL, Shen DL, Zhu K, Tang JN, Hai QM, Zhang JY. Levels of interleukin-33 and interleukin-6 in patients with acute coronary syndrome or stable angina. Clin Invest Med. 2013;36:234-41.

Tanindi A, Sahinarslan A, Elbeg S, Cemri M. Relation between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical presentation, extent and severity of atherosclerotic coronary artery disease. Open Cardiovascular Med J. 2011;5:110-6.

Gach O, Legrand V, Biessaux Y, Chapelle JP, Vanbelle S, Pierard LA. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol. 2007;99:31-5.

Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schächinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 2001;37:839-46.

Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med. 2003;114:715-22.

Hsieh IC, Chen CC, Hsieh MJ, Yang CH, Chen DY, Chang SH, et al. Prognostic impact of 9-month high-sensitivity C-reactive protein levels on long-term clinical outcomes and in-stent restenosis in patients at 9 months after drug-eluting stent implantation. PLoS One. 2015;10:0138512.

Herrmann J, Lennon RJ, Barsness GW, Sandhu GS, Gulati R, Best PJ, et al. High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary practice. Circ Cardiovasc Interv. 2012;5:783-90.

Xu YL, Li JJ, Xu B, Zhu CG, Yang YJ, Chen JL, et al. Role of plasma C-reactive protein in predicting in-stent restenosis in patients with stable angina after coronary stenting. Chin Med J (Engl). 2011;124:845-50.

Zhu X, Chen Y, Xiang L, You T, Jiao Y, Xu W, et al. The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis. Medicine (Baltimore). 2018;97:10679.

Chen SL, Liu Y, Lin L, Ye F, Zhang JJ, Tian NL. Interleukin-6, but not C-reactive protein, predicts the occurrence of cardiovascular events after drug-eluting stent for unstable angina. J Interv Cardiol. 2014;27:142-54.

Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart. 2000;84:83-7.

Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Connelly PW, et al. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J. 2004;25:1029-35.